Schrödinger today announced the appointment of veteran pharmaceutical executive Gary Sender to its Board of Directors, as well as his appointment to Chair of the Audit Committee. Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.
“Gary’s business and finance expertise across entrepreneurial startups and large pharmaceutical companies will be invaluable as we continue to advance our proprietary drug discovery pipeline and expand our partnerships with leading biopharma teams around the world,” said Ramy Farid, Ph.D., Schrödinger’s Chief Executive Officer. “We’re excited to work with him and add his capabilities to our Board.”
“I am honored to join Schrödinger during this exciting time, as the drug development team advances promising internal programs while continuing to build an impressive partnered pipeline,” said Mr. Sender. “Schrödinger’s computational platform unlocks tremendous opportunity for drug discovery and I look forward to working with the team to help navigate this expanding frontier.”
Mr. Sender currently serves as the Chief Financial Officer of Nabriva Therapeutics, a publicly traded biopharmaceutical company developing new antibiotics to treat infectious diseases. In that role, he has raised over $200 million in equity and debt capital, and provided the financial support for the acquisition of a private antibiotics firm with a late-stage asset, among other accomplishments. Prior to joining Nabriva, Mr. Sender served as Chief Financial Officer and Executive Vice President at Synergy Pharmaceuticals, and Senior Vice President of Finance at Shire, supporting its specialty pharmaceuticals and global commercial businesses. Earlier in his career, Mr. Sender was the founding Chief Financial Officer of Tengion, Inc., a regenerative medicine company. He also spent 15 years in several leadership roles within Merck & Co. Mr. Sender received his bachelor’s degree in business administration from Boston University and an MBA from Carnegie Mellon University.
Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading pharmaceutical, biotechnology, chemical, and electronics companies worldwide. In addition to this substantial and growing global business, Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Visit schrodinger.com for more information.